WO2025140708 - PYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/140708
Publication Date
03.07.2025
International Application No.
PCT/CN2024/143829
International Filing Date
30.12.2024
Title **
[English]
PYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF
[French]
COMPOSÉ PYRAZOLOPYRIMIDINE ET SON UTILISATION PHARMACEUTIQUE
[Chinese]
吡唑并嘧啶类化合物及其医药用途
Applicants **
ZHEJIANG PANTHEON INNOVATION PHARMACEUTICAL CO., LTD.
Inventors
ZHANG, Fengmin
ZHANG, Sicheng
Priority Data
202311861173.8
31.12.2023
CN
202411801131.X
09.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2000 | |
| EPO | Filing, Examination, Granting | 13618 | |
| Japan | Filing, Examination, Granting | 2246 | |
| South Korea | Filing, Examination, Granting | 2364 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
24,968
Contact Us
Abstract[English]
An NLRP3 inhibitor, a preparation method therefor and a pharmaceutical use thereof. Provided are an NLRP3 inhibitor of formula (I), a composition thereof and a use thereof. The compound can be used for treating or preventing diseases or conditions related to abnormal expression of an NLRP3 signaling pathway.[French]
L'invention concerne un inhibiteur de NLRP3, son procédé de préparation et son utilisation pharmaceutique. L'invention concerne un inhibiteur de NLRP3 de formule (I), une composition associée et une utilisation associée. Le composé peut être utilisé pour traiter ou prévenir des maladies ou des états liés à l'expression anormale d'une voie de signalisation NLRP3.[Chinese]
一种NLRP3抑制剂、其制备方法及其在医药上的应用。提供了一种式(I)所述NLRP3抑制剂及其组合物和用途，所述化合物可以用于治疗或预防NLRP3信号通路异常表达相关的疾病或病症。